GleamWall
中文EN

CTOR CITIUS ONCOLOGY, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1851484 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-73.3%
TTM EPS YoY-26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-126.6%
ROA-45.2%
ROIC (approx.)-132.9%
Asset turnover—

Leverage & solvency

Liabilities / assets64.0%
Debt / equity0.00x
Current ratio0.73x
Interest coverage-128.56x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue——
R&D expense$6.42M$4.93M
SG&A expense$8.78M$8.15M
Operating income-$23.52M-$20.57M
Interest expense$218,032—
Pretax income-$23.70M-$20.57M
Income tax$1.06M$576,000
Net income-$24.76M-$21.15M
EPS (basic)-0.34-0.31
EPS (diluted)-0.34-0.31
Weighted avg. shares (diluted)73.27M68.05M
Balance sheet
Cash & equivalents$3.92M$112
Inventory$22.29M$8.27M
Current assets$27.54M$10.97M
Total assets$100.94M$84.37M
Current liabilities$49.49M$32.70M
Total liabilities$56.08M$38.23M
Shareholders' equity$44.87M$46.14M
Shares outstanding83.51M71.55M
Cash flow statement
Operating cash flow-$5.49M$126,353
Investing cash flow-$5.75M-$5.00M
Financing cash flow$15.17M$4.87M
Stock-based compensation$8.32M$7.50M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.